Effect Of Whole or Skimmed Milk Greek Yogurt on Integrated Muscle Protein Synthesis, Glucose Homeostasis, and Cognition in Post-Menopausal Women

Effect Of Whole or Skimmed Milk Greek Yogurt on Integrated Muscle Protein Synthesis, Glucose Homeostasis, And Cognition in Post-Menopausal Women

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07705724

Enrollment

Registered

2026-07-15

Start date

2026-10-01

Completion date

2029-04-01

Last updated

2026-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Menopause, Obesity & Overweight, Women

Keywords

Muscle Protein Synthesis, Protein Turnover, Glycemic Control, Cognition, Post-Menopause, Women, Protein, Dairy

Brief summary

The study will examine the impact of adding two servings per day of skimmed or whole milk Greek yogurt on integrated muscle protein synthesis (iMPS), blood sugar control, and cognition in post-menopausal women with overweight and obesity.

Interventions

OTHERSkimmed vs Whole Milk Greek Yogurt

Participants will be randomized to receive a standardized diet with either skimmed milk or whole milk Greek yogurt.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

50 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

1. Aged 50 to 65 years 2. Body mass index ≥25 to \<40 kg/m2 or body fat ≥36% 3. Able to provide informed consent 4. Absence of menstruation for ≥12 months without the use of hormonal contraceptives, or one of the following: * Another medical cause of menopause e.g., history of bilateral oophorectomy * Clinician-confirmed menopausal status for those with hysterectomy and retained/unknown ovaries * Partial/total hysterectomy ≥12 months ago and current age ≥55 years

Exclusion criteria

1. Allergy or intolerance to dairy products (other allergies or intolerances may be excluded if they are not compatible with the study meals and how they are prepared) 2. Conditions, medications, or recent changes in medications that cause participants to be metabolically unstable (e.g., renal, cardiovascular, thyroid, polycystic ovary syndrome, type-1 and type-2 diabetes) 3. Gastric bypass/bariatric surgery in the previous 5 years 4. Pregnancy or nursing in the prior 12 months 5. Weight loss or gain \>5 kg in the last two months 6. Unable or unwilling to suspend use of blood thinning medications and non-steroidal anti-inflammatory drugs for the duration of the study 7. Unwilling to abstain from vigorous exercise for the study period 8. Does not or will not eat all foods on the standardized diet (e.g., allergies, intolerances, or taste preferences) 9. Participants may be excluded at the Principal Investigator's discretion if their health or body composition is not compatible with the required study procedures

Design outcomes

Primary

Measure	Time frame	Description
Integrated Muscle Protein Synthesis (iMPS)	1 week	Integrated muscle protein synthesis expressed as the fractional synthetic rate (%/day).

Secondary

Measure	Time frame	Description
Glucose Homeostasis	1 week	Mean glucose and mean amplitude of glucose excursions (MAGE) as determined from continuous glucose monitors (CGMs) (mg/dL).

Countries

United States

Contacts

CONTACTDavid D. Church, PhD

dchurch@uams.edu501-526-5769

CONTACTJoseph J Matthews, PhD

jmatthews@uams.edu501-526-5707

PRINCIPAL_INVESTIGATORDavid D Church, PhD

University of Arkansas

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 31, 2026